Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1744 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Today is Veterans Day November 11, 2020 FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... July 1, 2024 Load more HOT NEWS What to Know About the Different Types of Mastectomies for Breast... Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC
